Evidence map›Paper›PMID 28880927›Full record

ArticlePloS one2017

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.

Lei L Chen, Jing Zhu, Jonathan Schumacher, Chongjuan Wei, Latha Ramdas, Victor G Prieto, Arnie Jimenez, Marco A Velasco, Sheryl R Tripp, Robert H I Andtbacka and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. c-Kit deficiency impairs nitric oxide signaling in smooth muscle cells.Biochemical and biophysical research communications · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Lei L ChenDepartment of Sarcoma, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.ORCID http://orcid.org/0000-0002-0124-757X
Jing ZhuDepartment of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
Jonathan SchumacherARUP Laboratories, Salt Lake City, Utah, United States of America.
Chongjuan WeiDepartment of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
Latha RamdasResearch Information Services & Technology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
Victor G PrietoPathology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
Arnie JimenezVel-Lab Research, Missouri City, Texas, United States of America.
Marco A VelascoVel-Lab Research, Missouri City, Texas, United States of America.
Sheryl R TrippARUP Laboratories, Salt Lake City, Utah, United States of America.
Robert H I AndtbackaDepartment of Surgery, University of Utah, Salt Lake City, Utah, United States of America.
Launce GouwDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah, United States of America.
George M RodgersARUP Laboratories, Salt Lake City, Utah, United States of America.
Liansheng ZhangDepartment of Hematology & Oncology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, P. R. China.
Benjamin K ChanDepartment of Biology, University of Utah, Salt Lake City, Utah, United States of America.
Pamela B CassidyDepartment of Dermatology, University of Utah, Salt Lake City, Utah, United States of America.
Robert S BenjaminDepartment of Sarcoma, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
Sancy A LeachmanDepartment of Dermatology, University of Utah, Salt Lake City, Utah, United States of America.
Marsha L FrazierDepartment of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
The University of Texas MD Anderson Cancer Center · USUniversity of Utah · USARUP Laboratories (United States) · USLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We demonstrate that SCF-KIT signaling induces synthesis and secretion of endothelin-3 (ET3) in human umbilical vein endothelial cells and melanoma cells in vitro, gastrointestinal stromal tumors, human sun-exposed skin, and myenteric plexus of human colon post-fasting in vivo. This is the first report of a physiological mechanism of ET3 induction. Integrating our finding with supporting data from literature leads us to discover a previously unreported pathway of nitric oxide (NO) generation derived from physiological endothelial NO synthase (eNOS) or neuronal NOS (nNOS) activation (referred to as the KIT-ET3-NO pathway). It involves: (1) SCF-expressing cells communicate with neighboring KIT-expressing cells directly or indirectly (cleaved soluble SCF). (2) SCF-KIT signaling induces timely local ET3 synthesis and secretion. (3) ET3 binds to ETBR on both sides of intercellular space. (4) ET3-binding-initiated-ETBR activation increases cytosolic Ca2+, activates cell-specific eNOS or nNOS. (5) Temporally- and spatially-precise NO generation. NO diffuses into neighboring cells, thus acts in both SCF- and KIT-expressing cells. (6) NO modulates diverse cell-specific functions by NO/cGMP pathway, controlling transcriptional factors, or other mechanisms. We demonstrate the critical physiological role of the KIT-ET3-NO pathway in fulfilling high demand (exceeding basal level) of endothelium-dependent NO generation for coping with atherosclerosis, pregnancy, and aging. The KIT-ET3-NO pathway most likely also play critical roles in other cell functions that involve dual requirement of SCF-KIT signaling and NO. New strategies (e.g. enhancing the KIT-ET3-NO pathway) to harness the benefit of endogenous eNOS and nNOS activation and precise NO generation for correcting pathophysiology and restoring functions warrant investigation.

Indexed as

AtherosclerosisCell Line, TumorEndothelin-3Endothelium, VascularEnzyme-Linked Immunosorbent AssayGastrointestinal MotilityGastrointestinal Stromal TumorsHomeostasisHumansHuman Umbilical Vein Endothelial CellsImmunohistochemistryMelanomaMyenteric PlexusNeoplasm InvasivenessNitric OxideNitric Oxide Synthase Type IEndothelin-3Nitric OxideNitric Oxide Synthase Type INitric Oxide Synthase Type IIIProto-Oncogene Proteins c-kitReceptor, Endothelin BStem Cell Factor

Identifiers

PMID28880927
PMCPMC5589172
OpenAlexW2751075287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.